Novavax, Inc. (Nasdaq: NVAX) has announced a significant milestone in the fight against COVID-19 with the recent approval of its Biologics License Application (BLA) for the Nuvaxovid vaccine by the U.S. Food and Drug Administration (FDA). This vaccine is specifically indicated for active immunization against coronavirus disease 2019 (COVID-19) in adults aged 65 and older, as well as individuals aged 12 to 64 who suffer from at least one underlying condition that places them at high risk of severe outcomes from the virus.
The FDA’s approval comes as a vital step in providing these vulnerable populations with access to a protein-based, non-mRNA COVID-19 vaccine option. John C. Jacobs, President and Chief Executive Officer of Novavax, emphasized the importance of this development, stating, “Today’s approval solidifies a pathway for Americans aged 65 and older and those aged 12 through 64 with an underlying condition to have access to this essential vaccine.”
The approval not only marks a pivotal achievement for Novavax but also triggers a $175 million milestone payment from Sanofi as part of their collaborative agreement. Sanofi will spearhead the commercialization efforts for Nuvaxovid, while Novavax will benefit from ongoing tiered royalties from future COVID-19 vaccine sales.
The FDA’s decision was based on the compelling data obtained from a Phase 3 clinical trial, which demonstrated that Nuvaxovid was both safe and effective in preventing COVID-19. In addition, the FDA has mandated a new postmarketing commitment (PMC) that requires Novavax to conduct a Phase 4 efficacy and safety trial specifically targeting individuals aged 50 to 64 who do not have high-risk conditions for severe COVID-19. Novavax is currently collaborating with Sanofi to secure the necessary funding and to implement this trial.
Looking ahead, Novavax is optimistic about its plans for the upcoming vaccination season. The company anticipates being ready for the commercial rollout of the COVID-19 vaccine formula for the 2025-2026 season in partnership with Sanofi. This initiative is contingent upon the strain recommendations made at the upcoming FDA Vaccines and Related Biological Products Advisory Committee meeting scheduled for May 22, 2025.
Nuvaxovid has been available under Emergency Use Authorization in the United States since July 2022 and has already received full market approvals in several countries, including the European Union, the United Kingdom, Japan, Canada, Australia, Taiwan, and Singapore.
As COVID-19 continues to present challenges, the approval of Nuvaxovid offers hope to high-risk individuals seeking vaccination options that best meet their health needs.
